AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10225073 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-shot spinal anaesthesia (SS) with 17.5 mg bupivacaine
Number of subjects: 60
Study 10225073 — intervention group
Group type: COMPARATOR
Intervention: Continuous spinal analgesia (CSA) starting with 5 mg bupivacaine and incremental doses of 2.5 mg
Number of subjects: 60
Study 10225073 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative assessment
Number of subjects: 60
Study 8931786 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir induction therapy for 21 days
Number of subjects: 45
Study 8931786 — intervention group
Group type: EXPERIMENTAL
Intervention: High CMV load at presentation
Number of subjects: 45
Study 8931786 — intervention group
Group type: EXPERIMENTAL
Intervention: High CMV load in blood
Number of subjects: 45
Study 8351363 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced infusion (FI) of urokinase (UK)
Number of subjects: 25
Study 8351363 — intervention group
Group type: COMPARATOR
Intervention: Conventional slow continuous infusion (CI) of urokinase (UK)
Number of subjects: 25
Study 8351363 — intervention group
Group type: EXPERIMENTAL
Intervention: Lytic therapy (both FI and CI)
Number of subjects: 25
Study 2875479 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzo-pyrone (Paroven/Venoruton, Zyma)
Number of subjects: 16
Study 2875479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30265093 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonadiabatic holonomic single-qubit quantum gates on transmon qubit
Number of subjects: 0
Study 30265093 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonadiabatic holonomic single-qubit quantum gates on microwave cavity
Number of subjects: 0
Study 27144837 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 minutes of direct vibration (0-170 Hz)
Number of subjects: 11
Study 27144837 — intervention group
Group type: COMPARATOR
Intervention: Control (no vibration)
Number of subjects: 11
Study 23302490 — intervention group
Group type: EXPERIMENTAL
Intervention: Biotin deficiency
Number of subjects: 16
Study 23302490 — intervention group
Group type: EXPERIMENTAL
Intervention: Biotin sufficiency
Number of subjects: 16
Study 23302490 — intervention group
Group type: EXPERIMENTAL
Intervention: Biotin supplementation
Number of subjects: 16
Study 23302490 — intervention group
Group type: EXPERIMENTAL
Intervention: Biotin transporters and carboxylases
Number of subjects: 16
Study 22072347 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy + acupressure
Number of subjects: 40
Study 22072347 — intervention group
Group type: COMPARATOR
Intervention: Information session
Number of subjects: 40
Study 19266381 — intervention group
Group type: EXPERIMENTAL
Intervention: Viagra plus sex therapy (VST)
Number of subjects: 0
Study 19266381 — intervention group
Group type: COMPARATOR
Intervention: Viagra-only (VO)
Number of subjects: 0
Study 17570832 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D
Number of subjects: 196
Study 17570832 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D+C
Number of subjects: 196
Study 15454133 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerounding (one afternoon telerounding visit)
Number of subjects: 85
Study 15454133 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic telerounding (substitution of one daily bedside round with a robotic telerounding visit)
Number of subjects: 85
Study 15454133 — intervention group
Group type: COMPARATOR
Intervention: Standard once-daily attending bedside rounds
Number of subjects: 85
Study 11432326 — intervention group
Group type: EXPERIMENTAL
Intervention: Flonivin BS (Bacillus Subtilis IP 5832), 3 x 2 capsules daily for 7 days
Number of subjects: 63
Study 11432326 — intervention group
Group type: EXPERIMENTAL
Intervention: Flonivin BS (Bacillus Subtilis IP 5832)
Number of subjects: 63
Study 11432326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 9209778 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin 300 mg
Number of subjects: 10
Study 9209778 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin 600 mg
Number of subjects: 10
Study 8218619 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 0
Study 3696303 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (150 mg daily for three consecutive days, once every two weeks)
Number of subjects: 82
Study 3696303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 3696303 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 82
Study 29778403 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum induction
Number of subjects: 124
Study 27438322 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 18201
Study 27438322 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18201
Study 23926058 — intervention group
Group type: EXPERIMENTAL
Intervention: 200-600 mg TPD
Number of subjects: 40
Study 23926058 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg linezolid twice/day
Number of subjects: 40
Study 23926058 — intervention group
Group type: EXPERIMENTAL
Intervention: TPD with food
Number of subjects: 40
Study 23926058 — intervention group
Group type: EXPERIMENTAL
Intervention: TPD or tedizolid phosphate
Number of subjects: 40
Study 23926058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 22285055 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amoxicillin syrup (90 mg/kg per day in two doses for 5 days)
Number of subjects: 4410
Study 22285055 — intervention group
Group type: COMPARATOR
Intervention: Oral co-trimoxazole (one dose) and referral for admission and intravenous antibiotics
Number of subjects: 4410
Study 19342110 — intervention group
Group type: EXPERIMENTAL
Intervention: DDDR pacing
Number of subjects: 60
Study 19342110 — intervention group
Group type: COMPARATOR
Intervention: AAIR pacing
Number of subjects: 60
Study 18521899 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin-based chemotherapy
Number of subjects: 1953
Study 18521899 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin alone
Number of subjects: 1953
Study 18521899 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin combined with ifosfamide
Number of subjects: 1953
Study 17092415 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed therapy
Number of subjects: 33
Study 17092415 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 33
Study 12679215 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg
Number of subjects: 551
Study 12679215 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg
Number of subjects: 551
Study 12679215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 551
Study 12679215 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg (Black patients)
Number of subjects: 551
Study 12679215 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg (Black patients)
Number of subjects: 551
Study 12679215 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Black patients)
Number of subjects: 551
Study 12679215 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone 50 mg (White patients)
Number of subjects: 551
Study 12679215 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg (White patients)
Number of subjects: 551
Study 12679215 — intervention group
Group type: COMPARATOR
Intervention: Placebo (White patients)
Number of subjects: 551
Study 11263532 — intervention group
Group type: COMPARATOR
Intervention: No stimulation (group I)
Number of subjects: 87
Study 11263532 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant FSH 150 IU/day for 3 days (group II)
Number of subjects: 87
Study 11263532 — intervention group
Group type: EXPERIMENTAL
Intervention: IVM period of 28 hours
Number of subjects: 87
Study 11263532 — intervention group
Group type: COMPARATOR
Intervention: IVM period of 36 hours
Number of subjects: 87
Study 11263532 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycles with an increase in oestradiol concentration
Number of subjects: 87
Study 11263532 — intervention group
Group type: COMPARATOR
Intervention: Cycles without an increase in oestradiol concentration
Number of subjects: 87
Study 11263532 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycles with an increase in inhibin A concentration
Number of subjects: 87
Study 11263532 — intervention group
Group type: COMPARATOR
Intervention: Cycles without an increase in inhibin A concentration
Number of subjects: 87
Study 11263532 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall pregnancy rate per aspiration
Number of subjects: 87
Study 11263532 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall pregnancy rate per transfer
Number of subjects: 87
Study 9023710 — intervention group
Group type: COMPARATOR
Intervention: Captopril therapy
Number of subjects: 0
Study 9023710 — intervention group
Group type: COMPARATOR
Intervention: Captopril plus Tissue plasminogen activator
Number of subjects: 0
Study 9023710 — intervention group
Group type: COMPARATOR
Intervention: Perindopril therapy
Number of subjects: 0
Study 9023710 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibition in a subgroup of AMI patients
Number of subjects: 0
Study 2035381 — intervention group
Group type: EXPERIMENTAL
Intervention: Bruce-Standing Recovery
Number of subjects: 18
Study 2035381 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrupt Exercise
Number of subjects: 18
Study 2035381 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm-Up Exercise
Number of subjects: 18
Study 2035381 — intervention group
Group type: EXPERIMENTAL
Intervention: Bruce-Supine Recovery
Number of subjects: 18
Study 7049966 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 55
Study 7049966 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 55
Study 30787343 — intervention group
Group type: EXPERIMENTAL
Intervention: d[Ca] 1.75 mmol/L
Number of subjects: 19
Study 30787343 — intervention group
Group type: COMPARATOR
Intervention: d[Ca] 1.25 mmol/L
Number of subjects: 19
Study 28893387 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care + Pulsed Electromagnetic Frequency (PEMF) therapy
Number of subjects: 75
Study 28893387 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 75
Study 25425475 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 120 mg subcutaneously every 4 weeks (Q4W)
Number of subjects: 0
Study 25425475 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic acid 4 mg intravenously every 4 weeks (Q4W)
Number of subjects: 0
Study 24535482 — intervention group
Group type: EXPERIMENTAL
Intervention: 13.5 mg hyperbaric bupivacaine with 2 mg preservative-free ketorolac
Number of subjects: 62
Study 24535482 — intervention group
Group type: COMPARATOR
Intervention: 13.5 mg hyperbaric bupivacaine with spinal saline
Number of subjects: 62
Study 24535482 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 62
Study 22828593 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordinated messages (brochures, posters) encouraging clinic attendance
Number of subjects: 21057
Study 19176543 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg asoprisnil daily for 12 weeks
Number of subjects: 33
Study 19176543 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg asoprisnil daily for 12 weeks
Number of subjects: 33
Study 19176543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 17996657 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon 8 mg
Number of subjects: 157
Study 17996657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study 15870415 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 302
Study 15870415 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 302
Study 15870415 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 302
Study 15870415 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture vs Waiting list
Number of subjects: 302
Study 15870415 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture vs Sham acupuncture
Number of subjects: 302
Study 15870415 — intervention group
Group type: EXPERIMENTAL
Intervention: Proportion of responders
Number of subjects: 302
Study 12473699 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular lidocaine
Number of subjects: 30
Study 12473699 — intervention group
Group type: COMPARATOR
Intervention: Intravenous sedation
Number of subjects: 30
Study 9674466 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutter treatment
Number of subjects: 14
Study 9674466 — intervention group
Group type: COMPARATOR
Intervention: Autogenic drainage (AD)
Number of subjects: 14
Study 8592286 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy and continuous passive motion (n = 21)
Number of subjects: 39
Study 8592286 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy only (n = 18)
Number of subjects: 39
Study 2228322 — intervention group
Group type: EXPERIMENTAL
Intervention: sulglycotide (oral, 200 mg t.i.d. for 6 weeks, n = 93)
Number of subjects: 187
Study 2228322 — intervention group
Group type: COMPARATOR
Intervention: sucralfate (oral, 1 g t.i.d. for 6 weeks, n = 94)
Number of subjects: 187
Study 346631 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% lactulose syrup
Number of subjects: 47
Study 31434528 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategy-based cognitive training (n = 33)
Number of subjects: 64
Study 31434528 — intervention group
Group type: COMPARATOR
Intervention: Knowledge-based training (active control group, n = 31)
Number of subjects: 64
Study 31586530 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin/ezetimibe combination (40/10 mg)
Number of subjects: 1687
Study 31586530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1687
Study 27899298 — intervention group
Group type: EXPERIMENTAL
Intervention: Menthol (0.1-500mM)
Number of subjects: 10
Study 27899298 — intervention group
Group type: COMPARATOR
Intervention: Inhibition of NO, EDHFs, or sensory nerves
Number of subjects: 10
Study 27899298 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% menthol gel (0.017mL·cm‐2)
Number of subjects: 10
Study 26497109 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterole (FF/VI) 200/25 μg
Number of subjects: 16
Study 26497109 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate/salmeterol (FP/SAL) 500/50 μg
Number of subjects: 16
Study 23621752 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-dose IFN
Number of subjects: 855
Study 23621752 — intervention group
Group type: COMPARATOR
Intervention: High-dose IFN
Number of subjects: 855
Study 23621752 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 855
Study 22185647 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored counselling to decrease sitting time, focusing on commute and work time, reinforced during the first 6 months followed by a 6-month maintenance period.
Number of subjects: 0
Study 22185647 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored counselling regarding leisure time to encourage family physical activities.
Number of subjects: 0
Study 22185647 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometer data collection from adults and children, fasting blood samples, diurnal heart rate variability, muscle activity measurements, fundamental motor skills assessment, and body composition measurements.
Number of subjects: 0
Study 17614242 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief family treatment (BFT)
Number of subjects: 45
Study 17614242 — intervention group
Group type: COMPARATOR
Intervention: Continuing care (regardless of treatment condition)
Number of subjects: 45
Study 16049191 — intervention group
Group type: EXPERIMENTAL
Intervention: Encoding memory task with low level of integration
Number of subjects: 0
Study 16049191 — intervention group
Group type: EXPERIMENTAL
Intervention: Encoding memory task with high level of integration
Number of subjects: 0
Study 16049191 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrieval memory task with low level of integration
Number of subjects: 0
Study 16049191 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrieval memory task with high level of integration
Number of subjects: 0
Study 16049191 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of event-related activation latencies
Number of subjects: 0
Study 12616666 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispersible tablets of everolimus (0.8 mg/m2, maximum 1.5 mg, bid)
Number of subjects: 19
Study 12616666 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispersible tablets of everolimus (1.5 mg) after a high-fat meal
Number of subjects: 19
Study 12616666 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispersible tablets of everolimus (1.5 mg)
Number of subjects: 19
Study 12616666 — intervention group
Group type: COMPARATOR
Intervention: Conventional tablets of everolimus (1.5 mg)
Number of subjects: 19
Study 11094885 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation complexes
Number of subjects: 85
Study 11094885 — intervention group
Group type: COMPARATOR
Intervention: Various rehabilitation complexes
Number of subjects: 85
Study 9026479 — intervention group
Group type: EXPERIMENTAL
Intervention: Bile acid perfusion (30% and 100% of bile acid output) with test meal
Number of subjects: 7
Study 9026479 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxiglumide infusion
Number of subjects: 7
Study 9026479 — intervention group
Group type: EXPERIMENTAL
Intervention: Bile acids added to test meal (30% of bile acid output)
Number of subjects: 7
Study 1393843 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine 10 mg daily
Number of subjects: 94
Study 1393843 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 80 mg twice daily
Number of subjects: 94
Study 3903501 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen therapy combined with chemotherapy
Number of subjects: 112
Study 3903501 — intervention group
Group type: COMPARATOR
Intervention: Estrogen therapy alone
Number of subjects: 112
Study 3903501 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 112
Study 3903501 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen combined with chemotherapy
Number of subjects: 112
Study 30550503 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutureless technique using Steristrip for skin apposition
Number of subjects: 50
Study 30550503 — intervention group
Group type: COMPARATOR
Intervention: Subcuticular technique with 6‐0 vicryl and 6‐0 prolene continuous subcuticular sutures
Number of subjects: 50
Study 29557060 — intervention group
Group type: EXPERIMENTAL
Intervention: TMZ + RT
Number of subjects: 122
Study 29557060 — intervention group
Group type: EXPERIMENTAL
Intervention: TMZ + IFNβ + RT
Number of subjects: 122
Study 27630374 — intervention group
Group type: EXPERIMENTAL
Intervention: 440µg of intravitreal sirolimus administered on days 0, 30, 60, 90, 120, and 150
Number of subjects: 24
Study 27630374 — intervention group
Group type: EXPERIMENTAL
Intervention: 880µg of intravitreal sirolimus administered on days 0, 60, and 120
Number of subjects: 24
Study 27630374 — intervention group
Group type: EXPERIMENTAL
Intervention: 440µg of intravitreal sirolimus
Number of subjects: 24
Study 27630374 — intervention group
Group type: EXPERIMENTAL
Intervention: 880µg of intravitreal sirolimus
Number of subjects: 24
Study 24191779 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintendo Wii exergames with threat-framed health messages
Number of subjects: 0
Study 24191779 — intervention group
Group type: COMPARATOR
Intervention: Regular physical education lessons with the same health messages
Number of subjects: 0
Study 22682339 — intervention group
Group type: EXPERIMENTAL
Intervention: HPA genotyping using real time PCR and PCR-RFLP
Number of subjects: 600
Study 18923386 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol every 2 weeks for 2 months (intensive phase) followed by every other month maintenance phase
Number of subjects: 94
Study 18923386 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 94
Study 18923386 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol treatment
Number of subjects: 94
Study 17519730 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl bolus of 0.7 microg/kg before infiltration with local anaesthetics (Group F1)
Number of subjects: 100
Study 17519730 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl bolus of 0.7 microg/kg plus 0.6 microg/kg fentanyl every 45 minutes (Group F2)
Number of subjects: 100
Study 17519730 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam bolus of 0.05 mg/kg plus continuous infusion 0.08 mg/kg per hour (both groups)
Number of subjects: 100
Study 15663280 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous chondrograft transplantation
Number of subjects: 50
Study 15663280 — intervention group
Group type: COMPARATOR
Intervention: Abrasive techniques
Number of subjects: 50
Study 11687773 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermia (434 MHz)
Number of subjects: 40
Study 11687773 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound
Number of subjects: 40
Study 9739441 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard chemotherapy (CMF)
Number of subjects: 689
Study 9739441 — intervention group
Group type: COMPARATOR
Intervention: Temporary ovarian ablation by treatment with a LHRH analogue (Zoladex, Goserlin)
Number of subjects: 689
Study 7981450 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 58
Study 7981450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 2663013 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 20
Study 2663013 — intervention group
Group type: COMPARATOR
Intervention: Atropine
Number of subjects: 20
Study 29535403 — intervention group
Group type: EXPERIMENTAL
Intervention: Amylose-rich wheat-based rusks (ARR)
Number of subjects: 10
Study 27992239 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective Criteria‐Based Rehabilitation (OCBR)
Number of subjects: 40
Study 27992239 — intervention group
Group type: COMPARATOR
Intervention: Usual Care Rehabilitation (UCR)
Number of subjects: 40
Study 26639149 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 269
Study 26639149 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil
Number of subjects: 269